Spasov A A, Kucheriavenko A F, Salaznikova O A
Eksp Klin Farmakol. 2009 Sep-Oct;72(5):31-4.
The hemorheological activity of a series of hypoglycemic drugs and the new antidiabetic agent RU-254 (9-diethylaminoethyl-2,3-dihydroimidazo[1, 2-a]benzimidazole dihydrochloride) was studied by comparative tests on rats with model diabetes. All the tested drugs reduce the number of ADP-activated platelet forms, inhibit platelet aggregation, and decrease the blood viscosity in both intact rats and the animals with streptosotocin-induced diabetes. RU-254 exhibited maximum activity with respect to a complex of hemorheological parameters. Glyclazide was less effective in this respect than RU-254, but exceeded the activity of both glybenclamide and glydifen.
通过对糖尿病模型大鼠进行对比试验，研究了一系列降糖药物和新型抗糖尿病药物RU - 254（9 - 二乙氨基乙基 - 2,3 - 二氢咪唑并[1,2 - a]苯并咪唑二盐酸盐）的血液流变学活性。所有受试药物均能减少ADP激活的血小板形态数量，抑制血小板聚集，并降低正常大鼠和链脲佐菌素诱导糖尿病大鼠的血液粘度。RU - 254在血液流变学参数综合方面表现出最大活性。在这方面，格列齐特的效果不如RU - 254，但超过了格列本脲和格列吡嗪的活性。
